WNT5A and melanoma: In a follow-up study, DeVito et al. reported that the inhibition of Wnt5a signaling enhanced the efficacy of immune checkpoint blockades in a mouse melanoma model, by thwarting tolerogenic DCs, decreasing Kynurenine levels and reducing PMN-MDSC infiltration in the TME [90].